Allergy Therapeutics Valuation

Is AGYT.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGYT.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGYT.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGYT.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGYT.F?

Key metric: As AGYT.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AGYT.F. This is calculated by dividing AGYT.F's market cap by their current revenue.
What is AGYT.F's PS Ratio?
PS Ratio	4.3x
Sales	UK£55.20m
Market Cap	UK£238.81m

AGYT.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.7x
Enterprise Value/EBITDA	-8.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AGYT.F's PS Ratio compare to its peers?

The above table shows the PS ratio for AGYT.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.5x
NKTR Nektar Therapeutics	2.1x	11.8%	US$201.1m
MDWD MediWound	9.2x	43.5%	US$187.0m
AQST Aquestive Therapeutics	7.6x	29.5%	US$438.6m
TBPH Theravance Biopharma	7.2x	20.3%	US$465.7m
AGYT.F Allergy Therapeutics	4.3x	19.2%	US$238.8m

Price-To-Sales vs Peers: AGYT.F is good value based on its Price-To-Sales Ratio (4.3x) compared to the peer average (6.6x).

Price to Sales Ratio vs Industry

How does AGYT.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 Companies	Price / Sales	Estimated Growth	Market Cap
OGN Organon	0.6x	-0.06%	US$4.16b
PRGO Perrigo	0.9x	3.4%	US$3.87b
BHC Bausch Health Companies	0.3x	1.5%	US$2.92b
AMRX Amneal Pharmaceuticals	1x	5.6%	US$2.60b

70 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: AGYT.F is expensive based on its Price-To-Sales Ratio (4.3x) compared to the US Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is AGYT.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGYT.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AGYT.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

-1.3%

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

4.8%

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

5.2%

-4.6%